Currently, several therapies that specifically inhibit TGFB2, such as antisense phosphorothioate oligodeoxynucleotide trabedersen (AP12009), have entered clinical development in patients with advanced cancers (Jaschinski et al., 2011). The gene discussed is TGFB2; the disease is cancer.